Home › Funds › RA CAPITAL MANAGEMENT, L.P. › JBIO
RA CAPITAL MANAGEMENT, L.P. position in JBIO
JADE BIOSCIENCES INC · Health Care
RA CAPITAL MANAGEMENT, L.P. reported holding 3,671,083 shares of JBIO (JADE BIOSCIENCES INC) in its Q2 2026 13F filing — a position valued at US$81.6M, representing 0.71% of its reported portfolio and ranking #29 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed JBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How RA CAPITAL MANAGEMENT, L.P.'s JBIO position evolved
RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in JBIO in Q2 2025 at 1,062,326 shares (US$10.6M). The position peaked in Q2 2026 at 3,671,083 shares, worth US$81.6M. Across 5 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 3,671,083 shares valued at US$81.6M. Notable position changes include a 246% increase in Q4 2025 (shares fell 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.06M | $10.61M | New |
| Q3 2025 | 1.06M | $9.17M | Hold |
| Q4 2025 | 3.67M | $56.64M | Add |
| Q1 2026 | 3.67M | $51.58M | Hold |
| Q2 2026 | 3.67M | $81.57M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 106 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), Venrock Adviser, LLC (US$71.6M), Bellevue Group AG (US$67.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Paradigm Biocapital Advisors LP 2.86M sh · $63.49M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Remedium Capital Partners, LLC 1.58M sh · $35.06M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Logos Global Management LP 1.12M sh · $25.00M · Q2 2026
- Versant Venture Management, LLC 991.78K sh · $22.04M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $21.93M · Q2 2026
- Foresite Capital Management VI LLC 886.67K sh · $19.70M · Q2 2026
More on RA CAPITAL MANAGEMENT, L.P.
FAQ
How long has RA CAPITAL MANAGEMENT, L.P. held JBIO?
RA CAPITAL MANAGEMENT, L.P. has disclosed JBIO holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is RA CAPITAL MANAGEMENT, L.P.'s current position in JBIO?
As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 3.67M shares of JBIO (JADE BIOSCIENCES INC), valued at $81.57M, representing 0.71% of its reported portfolio and ranking #29.
Has RA CAPITAL MANAGEMENT, L.P. been buying or selling JBIO?
In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in JBIO. The position peaked in Q2 2026 at 3.67M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, Venrock Adviser, LLC, Bellevue Group AG, among 106 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.